Peptides and supported peptides for treating skin diseases

Abstract

The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein is BBI.

1 . A composition comprising a fusion protein comprising a Bowman-Birk Inhibitor scaffold, wherein the trypsin loop and/or chymotrypsin loop of said inhibitor is replaced with a peptide having the sequence set forth in SEQ ID NO:1, and wherein said peptide binds to a vascular endothelial growth factor. 
     
     
         2 . The composition of  claim 1 , wherein said fusion protein comprises a polypeptide selected from SEQ ID NOs: 22, 23, and 24. 
     
     
         3 . A cosmetic or pharmaceutical composition comprising a fusion protein comprising a Bowman-Birk Inhibitor scaffold, wherein the trypsin loop and/or chymotrypsin loop of said inhibitor is replaced with a peptide having the sequence set forth in SEQ ID NO:1, and wherein said peptide binds to a vascular endothelial growth factor. 
     
     
         4 . The composition of  claim 3 , wherein said composition is capable of modulating angiogenesis. 
     
     
         5 . The composition of  claim 3 , wherein said fusion protein comprises a polypeptide selected from SEQ ID NOs: 22, 23, and 24. 
     
     
         6 . A method for modulating angiogenesis comprising:
 i) providing a composition comprising a fusion protein comprising a Bowman-Birk Inhibitor scaffold, wherein the trypsin loop and/or chymotrypsin loop of said inhibitor is replaced with a peptide having the sequence set forth in SEQ ID NO:1, and wherein said peptide binds to a vascular endothelial growth factor;   ii) providing a subject to be treated, wherein the subject has an angiogenic skin disorder; and   ii) topically applying said composition to said subject in an area in which angiogenesis modulation is desired.   
     
     
         7 . The method of  claim 6 , wherein said fusion protein comprises a polypeptide selected from SEQ ID NOs: 22, 23, and 24. 
     
     
         8 . A method for decreasing the activity of a vascular endothelial growth factor comprising the steps of:
 i) providing a subject, wherein the subject has an angiogenic skin disorder; and   ii) topically administering in an area in which the vascular endothelial growth factor inhibition is desired a composition comprising a Bowman-Birk Inhibitor scaffold, wherein the trypsin loop and/or chymotrypsin loop of said inhibitor is replaced with a peptide having the sequence set forth in SEQ ID NO:1, and wherein said peptide binds to a vascular endothelial growth factor.